Pretreatment Predictors of Death From Other Causes in Men With Prostate Cancer

Journal of Urology

Volumn 180, Issue 6, 2008, Pages 2447-2452

  Simone, Nicole L ^a   Singh, Anurag K ^b   Cowan, Janet E ^c   Soule, Benjamin P ^a   Carroll, Peter R ^c   Litwin, Mark S ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

mortality; prostatic neoplasms; therapeutics

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; EDUCATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SHORT FORM 36; SMOKING;

ADENOCARCINOMA; AGED; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 55549113526     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.08.017     Document Type: Article

References (20)

1. Cancer Facts and Figures 2007 (2007), American Cancer Society
2. Roemeling S., Roobol M.J., de Vries S.H., Wolters T., Gosselaar C., van Leenders G.J., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 (2007) 1244
3. Carter H.B., Walsh P.C., Landis P., and Epstein J.I. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167 (2002) 1231
4. Carter C.A., Donahue T., Sun L., Wu H., McLeod D.G., Amling C., et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21 (2003) 4001
5. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., and Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843
6. D'Amico A.V., Whittington R., Malkowicz S.B., Fondurulia J., Chen M.H., Kaplan I., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17 (1999) 168
7. Kattan M.W., Zelefsky M.J., Kupelian P.A., Scardino P.T., Fuks Z., and Leibel S.A. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18 (2000) 3352
8. Kattan M.W., Eastham J.A., Wheeler T.M., Maru N., Scardino P.T., Erbersdobler A., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792
9. Lubeck D.P., Litwin M.S., Henning J.M., Stier D.M., Mazonson P., Fisk R., et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48 (1996) 773
10. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
11. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582
12. Singh B., Bhaya M., Stern J., Roland J.T., Zimbler M., Rosenfeld R.M., et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 107 (1997) 1469
13. Battafarano R.J., Piccirillo J.F., Meyers B.F., Hsu H.S., Guthrie T.J., Cooper J.D., et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 123 (2002) 280
14. Newschaffer C.J., Bush T.L., and Penberthy L.T. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol 50 (1997) 725
15. West D.W., Satariano W.A., Ragland D.R., and Hiatt R.A. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 6 (1996) 413
16. Sabin S.L., Rosenfeld R.M., Sundaram K., Har-el G., and Lucente F.E. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J 78 (1999) 578
17. Boulos D.L., Groome P.A., Brundage M.D., Siemens D.R., Mackillop W.J., Heaton J.P., et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 106 (2006) 1804
18. Schrijvers C.T., Coebergh J.W., and Mackenbach J.P. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer 80 (1997) 1482
19. Mackillop W.J., Zhang-Salomons J., Groome P.A., Paszat L., and Holowaty E. Socioeconomic status and cancer survival in Ontario. J Clin Oncol 15 (1997) 1680
20. Satariano W.A., Ragland K.E., and Van Den Eeden S.K. Cause of death in men diagnosed with prostate carcinoma. Cancer 83 (1998) 1180